Studieoverzicht
Study name: PRT3789-01
| Histology | NSCLC |
|---|---|
| Tumor stage | Stage IV |
| Host / recruiting sites | LUMC |
| Enrollment | Recruiting |
| Therapy line | Later line (≥2L) |
| Design |
Open-label, multi-center, first-in-human fase 1 dosis escalatie studie |
| Intervention | PRT3789 |
| Key outcome parameters | Safety en tolerability |
| Key inclusion criteria | Advanced of gemetastaseerde solide maligniteit met SMARCA4 mutatie (NGS) of verlies van SMARCA4 (IHC) Progressie op standard of care systeemtherapie |
| Key exclusion criteria | Symptomatische CNS metastasen |
| Contact information | Log in voor de contactinformatie |